Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Biogenesis and Function of Circular RNAs in Health and in Disease.

Haddad G, Lorenzen JM.

Front Pharmacol. 2019 Apr 26;10:428. doi: 10.3389/fphar.2019.00428. eCollection 2019. Review.

2.

The hypoxic kidney: pathogenesis and noncoding RNA-based therapeutic strategies.

Haddad G, Kölling M, Lorenzen JM.

Swiss Med Wkly. 2019 Jan 13;149:w14703. doi: 10.4414/smw.2019.14703. eCollection 2019 Jan 1.

3.

Noncoding RNAs in acute kidney injury.

Brandenburger T, Salgado Somoza A, Devaux Y, Lorenzen JM.

Kidney Int. 2018 Nov;94(5):870-881. doi: 10.1016/j.kint.2018.06.033. Review.

PMID:
30348304
4.

The Circular RNA ciRs-126 Predicts Survival in Critically Ill Patients With Acute Kidney Injury.

Kölling M, Seeger H, Haddad G, Kistler A, Nowak A, Faulhaber-Walter R, Kielstein J, Haller H, Fliser D, Mueller T, Wüthrich RP, Lorenzen JM.

Kidney Int Rep. 2018 Jun 2;3(5):1144-1152. doi: 10.1016/j.ekir.2018.05.012. eCollection 2018 Sep.

5.

Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases.

Müller-Deile J, Dannenberg J, Schroder P, Lin MH, Miner JH, Chen R, Bräsen JH, Thum T, Nyström J, Staggs LB, Haller H, Fiedler J, Lorenzen JM, Schiffer M.

Kidney Int. 2017 Oct;92(4):836-849. doi: 10.1016/j.kint.2017.03.005. Epub 2017 May 3.

6.

Antagonism of profibrotic microRNA-21 improves outcome of murine chronic renal allograft dysfunction.

Schauerte C, Hübner A, Rong S, Wang S, Shushakova N, Mengel M, Dettling A, Bang C, Scherf K, Koelling M, Melk A, Haller H, Thum T, Lorenzen JM.

Kidney Int. 2017 Sep;92(3):646-656. doi: 10.1016/j.kint.2017.02.012. Epub 2017 Apr 8.

PMID:
28396121
7.

Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice.

Kölling M, Kaucsar T, Schauerte C, Hübner A, Dettling A, Park JK, Busch M, Wulff X, Meier M, Scherf K, Bukosza N, Szénási G, Godó M, Sharma A, Heuser M, Hamar P, Bang C, Haller H, Thum T, Lorenzen JM.

Mol Ther. 2017 Jan 4;25(1):165-180. doi: 10.1016/j.ymthe.2016.08.001. Epub 2017 Jan 4.

8.

Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hypertrophic cardiomyopathy.

Kitow J, Derda AA, Beermann J, Kumarswarmy R, Pfanne A, Fendrich J, Lorenzen JM, Xiao K, Bavendiek U, Bauersachs J, Thum T.

Am J Physiol Heart Circ Physiol. 2016 Sep 1;311(3):H707-12. doi: 10.1152/ajpheart.00194.2016. Epub 2016 Jul 15.

9.

Long noncoding RNAs in kidney and cardiovascular diseases.

Lorenzen JM, Thum T.

Nat Rev Nephrol. 2016 Jun;12(6):360-73. doi: 10.1038/nrneph.2016.51. Epub 2016 May 3. Review.

PMID:
27140855
10.

Long Noncoding RNAs in Urine Are Detectable and May Enable Early Detection of Acute T Cell-Mediated Rejection of Renal Allografts.

Lorenzen JM, Schauerte C, Kölling M, Hübner A, Knapp M, Haller H, Thum T.

Clin Chem. 2015 Dec;61(12):1505-14. doi: 10.1373/clinchem.2015.243600. Epub 2015 Oct 27.

11.

Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy.

Derda AA, Thum S, Lorenzen JM, Bavendiek U, Heineke J, Keyser B, Stuhrmann M, Givens RC, Kennel PJ, Schulze PC, Widder JD, Bauersachs J, Thum T.

Int J Cardiol. 2015 Oct 1;196:115-22. doi: 10.1016/j.ijcard.2015.05.185. Epub 2015 Jun 5.

12.

Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis.

Lorenzen JM, Schauerte C, Hübner A, Kölling M, Martino F, Scherf K, Batkai S, Zimmer K, Foinquinos A, Kaucsar T, Fiedler J, Kumarswamy R, Bang C, Hartmann D, Gupta SK, Kielstein J, Jungmann A, Katus HA, Weidemann F, Müller OJ, Haller H, Thum T.

Eur Heart J. 2015 Aug 21;36(32):2184-96. doi: 10.1093/eurheartj/ehv109. Epub 2015 Apr 21.

13.

Impairment of Wound Healing in Patients With Type 2 Diabetes Mellitus Influences Circulating MicroRNA Patterns via Inflammatory Cytokines.

Dangwal S, Stratmann B, Bang C, Lorenzen JM, Kumarswamy R, Fiedler J, Falk CS, Scholz CJ, Thum T, Tschoepe D.

Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1480-8. doi: 10.1161/ATVBAHA.114.305048. Epub 2015 Mar 26.

PMID:
25814674
14.

Vascular and circulating microRNAs in renal ischaemia-reperfusion injury.

Lorenzen JM.

J Physiol. 2015 Apr 15;593(8):1777-84. doi: 10.1113/JP270318. Epub 2015 Mar 31. Review.

15.

Circulating long noncoding RNATapSaki is a predictor of mortality in critically ill patients with acute kidney injury.

Lorenzen JM, Schauerte C, Kielstein JT, Hübner A, Martino F, Fiedler J, Gupta SK, Faulhaber-Walter R, Kumarswamy R, Hafer C, Haller H, Fliser D, Thum T.

Clin Chem. 2015 Jan;61(1):191-201. doi: 10.1373/clinchem.2014.230359. Epub 2014 Oct 7.

16.

Vascular importance of the miR-212/132 cluster.

Kumarswamy R, Volkmann I, Beermann J, Napp LC, Jabs O, Bhayadia R, Melk A, Ucar A, Chowdhury K, Lorenzen JM, Gupta SK, Batkai S, Thum T.

Eur Heart J. 2014 Dec 1;35(45):3224-31. doi: 10.1093/eurheartj/ehu344. Epub 2014 Sep 12.

PMID:
25217442
17.

Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study.

Osipova J, Fischer DC, Dangwal S, Volkmann I, Widera C, Schwarz K, Lorenzen JM, Schreiver C, Jacoby U, Heimhalt M, Thum T, Haffner D.

J Clin Endocrinol Metab. 2014 Sep;99(9):E1661-5. doi: 10.1210/jc.2013-3868. Epub 2014 Jun 17.

PMID:
24937532
18.

MicroRNA-24 antagonism prevents renal ischemia reperfusion injury.

Lorenzen JM, Kaucsar T, Schauerte C, Schmitt R, Rong S, Hübner A, Scherf K, Fiedler J, Martino F, Kumarswamy R, Kölling M, Sörensen I, Hinz H, Heineke J, van Rooij E, Haller H, Thum T.

J Am Soc Nephrol. 2014 Dec;25(12):2717-29. doi: 10.1681/ASN.2013121329. Epub 2014 May 22.

19.

Regulation of cardiac and renal ischemia-reperfusion injury by microRNAs.

Lorenzen JM, Batkai S, Thum T.

Free Radic Biol Med. 2013 Sep;64:78-84. doi: 10.1016/j.freeradbiomed.2013.06.044. Epub 2013 Jul 8. Review.

PMID:
23845966
20.

Detection and transport mechanisms of circulating microRNAs in neurological, cardiac and kidney diseases.

Lorenzen JM, Martino F, Thum T.

Curr Med Chem. 2013;20(29):3623-8. Review.

PMID:
23834179
21.

Cotrimoxazole plasma levels, dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of under-dosing using current dosing recommendations.

Clajus C, Kühn-Velten WN, Schmidt JJ, Lorenzen JM, Pietsch D, Beutel G, Kielstein JT.

BMC Pharmacol Toxicol. 2013 Apr 3;14:19. doi: 10.1186/2050-6511-14-19.

22.

MicroRNAs in idiopathic childhood nephrotic syndrome.

Lorenzen JM, Thum T.

Clin Chem. 2013 Apr;59(4):595-7. doi: 10.1373/clinchem.2013.202671. Epub 2013 Feb 11. No abstract available.

23.

Fetuin, matrix-Gla protein and osteopontin in calcification of renal allografts.

Lorenzen JM, Martino F, Scheffner I, Bröcker V, Leitolf H, Haller H, Gwinner W.

PLoS One. 2012;7(12):e52039. doi: 10.1371/journal.pone.0052039. Epub 2012 Dec 17.

24.

Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease.

Lorenzen JM, Dietrich B, Fiedler J, Jazbutyte V, Fleissner F, Karpinski N, Weidemann F, Wanner C, Asan E, Caprio M, Ertl G, Bauersachs J, Thum T.

Basic Res Cardiol. 2013 Jan;108(1):311. doi: 10.1007/s00395-012-0311-3. Epub 2012 Nov 20.

PMID:
23184391
25.

Circulating microRNAs in patients with Shiga-Toxin-producing E. coli O104:H4 induced hemolytic uremic syndrome.

Lorenzen JM, Menne J, Schmidt BM, Schmidt M, Martino F, Dietrich R, Samiri S, Worthmann H, Heeren M, Weissenborn K, Haller H, Schiffer M, Kielstein JT, Thum T.

PLoS One. 2012;7(10):e47215. doi: 10.1371/journal.pone.0047215. Epub 2012 Oct 11.

26.

Aromatase inhibition attenuates desflurane-induced preconditioning against acute myocardial infarction in male mouse heart in vivo.

Jazbutyte V, Stumpner J, Redel A, Lorenzen JM, Roewer N, Thum T, Kehl F.

PLoS One. 2012;7(8):e42032. doi: 10.1371/journal.pone.0042032. Epub 2012 Aug 2.

27.

Cardiac fibrosis revisited by microRNA therapeutics.

Thum T, Lorenzen JM.

Circulation. 2012 Aug 14;126(7):800-2. doi: 10.1161/CIRCULATIONAHA.112.125013. Epub 2012 Jul 18. No abstract available.

PMID:
22811579
28.

Circulating and urinary microRNAs in kidney disease.

Lorenzen JM, Thum T.

Clin J Am Soc Nephrol. 2012 Sep;7(9):1528-33. doi: 10.2215/CJN.01170212. Epub 2012 May 10. Review.

29.

Epigenetic modifications in cardiovascular disease.

Lorenzen JM, Martino F, Thum T.

Basic Res Cardiol. 2012 Mar;107(2):245. doi: 10.1007/s00395-012-0245-9. Epub 2012 Jan 11. Review.

30.

Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis.

Lorenzen JM, Broll M, Kaever V, Burhenne H, Hafer C, Clajus C, Knitsch W, Burkhardt O, Kielstein JT.

Clin J Am Soc Nephrol. 2012 Mar;7(3):385-90. doi: 10.2215/CJN.05690611. Epub 2012 Jan 5.

31.

Role of microRNAs in immunity and organ transplantation.

Spiegel JC, Lorenzen JM, Thum T.

Expert Rev Mol Med. 2011 Dec 8;13:e37. doi: 10.1017/S1462399411002080. Review.

PMID:
22152163
32.

Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients.

Lorenzen JM, Volkmann I, Fiedler J, Schmidt M, Scheffner I, Haller H, Gwinner W, Thum T.

Am J Transplant. 2011 Oct;11(10):2221-7. doi: 10.1111/j.1600-6143.2011.03679.x. Epub 2011 Aug 3.

33.

Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome.

Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, Kempf T, Wollert KC, Thum T.

J Mol Cell Cardiol. 2011 Nov;51(5):872-5. doi: 10.1016/j.yjmcc.2011.07.011. Epub 2011 Jul 23.

PMID:
21806992
34.

Circulating miR-210 predicts survival in critically ill patients with acute kidney injury.

Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kümpers P, Faulhaber-Walter R, Haller H, Fliser D, Thum T.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1540-6. doi: 10.2215/CJN.00430111. Epub 2011 Jun 23.

35.

MicroRNAs as mediators and therapeutic targets in chronic kidney disease.

Lorenzen JM, Haller H, Thum T.

Nat Rev Nephrol. 2011 May;7(5):286-94. doi: 10.1038/nrneph.2011.26. Epub 2011 Mar 22. Review.

PMID:
21423249
36.

Conversion from conventional in-centre thrice-weekly haemodialysis to short daily home haemodialysis ameliorates uremia-associated clinical parameters.

Lorenzen JM, Thum T, Eisenbach GM, Haller H, Kielstein JT.

Int Urol Nephrol. 2012 Jun;44(3):883-90. doi: 10.1007/s11255-011-9918-9. Epub 2011 Feb 27.

PMID:
21359832
37.

TLR-4+ peripheral blood monocytes and cardiovascular events in patients with chronic kidney disease--a prospective follow-up study.

Lorenzen JM, David S, Richter A, de Groot K, Kielstein JT, Haller H, Thum T, Fliser D.

Nephrol Dial Transplant. 2011 Apr;26(4):1421-4. doi: 10.1093/ndt/gfq758. Epub 2011 Jan 14.

PMID:
21239386
38.

Urinary asymmetric dimethylarginine (ADMA) is a predictor of mortality risk in patients with coronary artery disease.

Wolf C, Lorenzen JM, Stein S, Tsikas D, Störk S, Weidemann F, Ertl G, Anker SD, Bauersachs J, Thum T.

Int J Cardiol. 2012 May 3;156(3):289-94. doi: 10.1016/j.ijcard.2010.11.003. Epub 2010 Dec 14.

PMID:
21159392
39.

Osteopontin in patients with idiopathic pulmonary hypertension.

Lorenzen JM, Nickel N, Krämer R, Golpon H, Westerkamp V, Olsson KM, Haller H, Hoeper MM.

Chest. 2011 May;139(5):1010-1017. doi: 10.1378/chest.10-1146. Epub 2010 Oct 14.

PMID:
20947652
40.

Osteopontin predicts survival in critically ill patients with acute kidney injury.

Lorenzen JM, Hafer C, Faulhaber-Walter R, Kümpers P, Kielstein JT, Haller H, Fliser D.

Nephrol Dial Transplant. 2011 Feb;26(2):531-7. doi: 10.1093/ndt/gfq498. Epub 2010 Aug 23.

PMID:
20732925
41.

Osteopontin in the development of systemic sclerosis--relation to disease activity and organ manifestation.

Lorenzen JM, Krämer R, Meier M, Werfel T, Wichmann K, Hoeper MM, Riemekasten G, Becker MO, Haller H, Witte T.

Rheumatology (Oxford). 2010 Oct;49(10):1989-91. doi: 10.1093/rheumatology/keq223. Epub 2010 Jul 20. No abstract available.

PMID:
20647294
42.

SDMA is an early marker of change in GFR after living-related kidney donation.

Kielstein JT, Veldink H, Martens-Lobenhoffer J, Haller H, Burg M, Lorenzen JM, Lichtinghagen R, Bode-Böger SM, Kliem V.

Nephrol Dial Transplant. 2011 Jan;26(1):324-8. doi: 10.1093/ndt/gfq395. Epub 2010 Jul 9.

PMID:
20621932
43.

Necrotizing fasciitis and acute kidney injury in a patient with acute myelogenous leukemia-case presentation and review of the literature.

Lorenzen JM, Krauter J, Länger F, Haller H, Gwinner W.

Ann Hematol. 2011 Feb;90(2):235-8. doi: 10.1007/s00277-010-0995-0. Epub 2010 May 25. No abstract available.

PMID:
20499234
44.

Failed rescue therapy with rapamycin after paraquat intoxication.

Lorenzen JM, Schonenberger E, Hafer C, Hoeper M, Kielstein JT.

Clin Toxicol (Phila). 2010 Jan;48(1):84-6. doi: 10.3109/15563650903376089.

PMID:
19888892
45.

Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial.

Lorenzen JM, Neunhöffer H, David S, Kielstein JT, Haller H, Fliser D.

Atherosclerosis. 2010 Mar;209(1):184-8. doi: 10.1016/j.atherosclerosis.2009.09.009. Epub 2009 Sep 12.

PMID:
19801149
46.

Effects of arginase inhibitors on the contractile and relaxant responses of isolated human penile erectile tissue.

Lorenzen JM, Ückert S, Scheller F, Haller H, Kuczyk MA.

World J Urol. 2009 Dec;27(6):805-10. doi: 10.1007/s00345-009-0405-1.

PMID:
19360414

Supplemental Content

Loading ...
Support Center